Pharmaxis Ltd. announced that it has now received reports on all of the 13week toxicity studies conducted for each of its two Lysyl Oxidase Like 2 (LOXL2) inhibitors. Together with the previously released results of Pharmaxis phase 1 clinical trials for both compounds showing best in class target engagement from a once a day oral dose, Pharmaxis believes that this program is ready to enter phase 2 clinical studies for fibrotic diseases such as NonAlcoholic Steatohepatitis (NASH), cardiac fibrosis and Idiopathic Pulmonary Fibrosis (IPF). Both drug compounds were tested at a range of doses in two species over a 13week period to establish the No Observed Adverse Effect Level. For both compounds doses that resulted in 85% or greater inhibition of the target enzyme in the phase 1 studies were below the human equivalent NOAEL doses in all toxicity studies and therefore an adequate safety margin to start phase 2 studies of up to 3 months in length.